Key Highlights

  • Shares closed at $13.21 at last closing, up 1.15%.
  • Second-quarter 2026 Revenue was about $3.1 million, topping some forecasts, while the company reaffirmed its 2026 outlook.
  • Its marketed product NexoBrid is used for the removal of eschar in severe burns.
  • Lead candidate EscharEx is being developed for the debridement of chronic wounds, a large potential market.

MediWound (NASDAQ:MDWD) is a biopharmaceutical company focused on wound care and tissue repair, with products and candidates that use enzymatic technologies to remove dead or damaged tissue. Shares closed at $13.21 at last closing, up 1.15%.

Its marketed product NexoBrid is used for the removal of eschar in severe burns, and its lead candidate, EscharEx, is being developed for the debridement of chronic wounds, a large potential market. As a small company with limited revenue and ongoing losses, its value depends on the commercialization of NexoBrid and the development of EscharEx.

Latest Developments

In its second-quarter 2026 results, MediWound reported revenue of about $3.1 million, topping some forecasts, while posting a loss and reaffirming its 2026 outlook. Investors should confirm the latest revenue, NexoBrid sales trends, EscharEx clinical and regulatory progress, net loss and cash position, and guidance directly from SEC filings.

Financial and Business Position

MediWound's financial position is defined by modest revenue, primarily from NexoBrid and related agreements, ongoing operating losses as it develops EscharEx, and its cash, which funds its operations and development. Investors should watch revenue and NexoBrid sales, EscharEx clinical and regulatory progress including any pivotal data, net loss and cash burn, and the cash position.

Stock-Market Context

MDWD shares closed at $13.21 at last closing, up 1.15%. The stock is a small-cap biopharmaceutical company whose shares are volatile and sensitive to clinical and regulatory developments for EscharEx, NexoBrid sales trends, and financings.

What Investors Should Watch

Watch revenue and NexoBrid sales trends, EscharEx clinical and regulatory progress including any pivotal readout, net loss and cash burn, the cash position, and any Capital raises. Positive EscharEx data and progress toward approval, combined with growing NexoBrid sales, would be the most direct factors that could support continued momentum.